Low- and high-dose aspirin achieve similar protection, safety for those with heart disease
Presented at ACC.21, the findings are from the largest aspirin dosing trial conducted in routine care and clinical settings using PCORnet, a national resource advancing more efficient clinical research
Published 2021-05-17 · Original archive entry · Explore research explainers
WASHINGTON, DC--People with cardiovascular disease (CVD) taking aspirin to lower their chances of suffering a heart attack or stroke experienced similar health benefits, including reduced death and hospitalization for heart attack and stroke, whether they took a high or low dose of aspirin, according to a study presented today at ACC.21, the American College of Cardiology's 70th Annual Scientific Session and published in the New England Journal of Medicine.
CVD--and atherosclerosis, in particular, which is a narrowing and hardening of the arteries--is a leading cause of death for men, women, and most racial and ethnic groups in the United States, with estimated direct costs of END
CVD--and atherosclerosis, in particular, which is a narrowing and hardening of the arteries--is a leading cause of death for men, women, and most racial and ethnic groups in the United States, with estimated direct costs of END